Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 50

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Infertility

Not recruiting

Study on Subfertility: Comparing Estradiol Valerate and Micronised Progesterone for Frozen-Thawed Embryo Transfer in Women Seeking Pregnancy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Estradiol Valerate
  • Sponsor:UZ Leuven

Prostate cancer

Not recruiting

Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:64CU-PSMA I&T
  • Sponsor:Curium US LLC

Hypogonadism male

Not recruiting

Study on the Effects and Safety of Lutropin Alfa and hCG in Men with Hypogonadotropic Hypogonadism

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Lutropin Alfa
  • Sponsor:Department Of Biomedical Metabolic And Neural Sciences

Hormone-refractory prostate cancer+2

Not recruiting

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Breast cancer

Not recruiting

Study on Personalized Treatment for High-Risk Breast Cancer Using Palbociclib, Olaparib, and Pertuzumab in Patients with Advanced Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Helse Bergen HF

Breast cancer+4

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Institut fuer Frauengesundheit GmbH

Prostate cancer+1

Not recruiting

Study on the Safety of Lutetium (177Lu) Zadavotide Guraxetan and Radium Ra 223 Dichloride for Patients with Bone-Metastatic Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) zadavotide guraxetan
  • Sponsor:Amsterdam UMC Stichting

Neuroendocrine carcinoma of the skin+4

Not recruiting

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BT-001
  • Sponsor:Transgene

Anogenital warts

Not recruiting

Study of HPV vaccine to prevent recurrence of External Genital Warts in previously cured patients: Comparing Human Papillomavirus vaccine versus placebo

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer+2

Not recruiting

Study on the Safety and Effectiveness of PF-07104091 Alone or with Fulvestrant, Letrozole, and Palbociclib for Patients with Advanced Breast, Ovarian, or Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Ovarian cancer recurrent

Not recruiting

Study of Azenosertib and Niraparib for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Penile squamous cell carcinoma

Not recruiting

Study on Avelumab for Patients with Advanced or Metastatic Squamous Cell Penile Cancer After Initial Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier Regional Universitaire

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.